Derniers essais


EudraCT Number: 2022-002312-23 Sponsor Protocol Number: LY06006/MRCT-301 Start Date: 2023-05-25
Sponsor Name: Shandong Boan Biotechnology Co., Ltd.
Full Title: A randomized, double-blind, parallel-group, active-controlled comparative study to evaluate the efficacy, safety, pharmacokinetics, and immunogenicity of LY06006 compared with EU-Prolia in postmeno...
Medical condition: Postmenopausal osteoporosis
Disease: Version SOC Term Classification Code Term Level
20.0 10028395 - Musculoskeletal and connective tissue disorders 10031285 Osteoporosis postmenopausal PT
Population Age: Adults, Elderly Gender: Female
Trial protocol: BG (Ongoing) CZ (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-003475-42 Sponsor Protocol Number: GTAEXS617-001 Start Date: 2023-05-23
Sponsor Name: Exscientia AI Ltd
Full Title: A Phase 1/2 open-label multicenter study to assess the safety, pharmacokinetics, and anti-tumor activity of GTAEXS617 in patients with advanced solid tumors.
Medical condition: advanced solid tumors
Disease: Version SOC Term Classification Code Term Level
21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052360 Colorectal adenocarcinoma PT
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10051971 Pancreatic adenocarcinoma LLT
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006204 Breast carcinoma LLT
20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061328 Ovarian epithelial cancer PT
21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: BE (Trial now transitioned)
Trial results: (No results available)
EudraCT Number: 2022-002407-37 Sponsor Protocol Number: BET-PSMA-121 Start Date: 2023-05-22
Sponsor Name: Blue Earth Therapeutics Limited
Full Title: An open-label, multicentre, integrated Phase 1 & 2 study to evaluate the safety, tolerability, radiation dosimetry and anti-tumour activity of Lutetium (177Lu) rhPSMA-10.1 injection in men with met...
Medical condition: PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)
Disease: Version SOC Term Classification Code Term Level
21.1 100000004864 10076506 Castration-resistant prostate cancer LLT
Population Age: Adults, Elderly Gender: Male
Trial protocol: DE (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-003398-51 Sponsor Protocol Number: R-Pola-Glo Start Date: 2023-05-16
Sponsor Name: Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest
Full Title: A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in...
Medical condition: aggressive large B-cell lymphoma
Disease: Version SOC Term Classification Code Term Level
20.0 100000004851 10012819 Diffuse large B-cell lymphomas HLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing)
Trial results: (No results available)
EudraCT Number: 2022-001781-35 Sponsor Protocol Number: UKER-BC007-01 Start Date: 2023-05-16
Sponsor Name: Universitätsklinikum Erlangen
Full Title: Prospective, explorative, randomized, controlled, double-blind, cross-over phase IIa clinical trial to investigate safety and tolerability as well as potential clinical effects of BC007 in patients...
Medical condition: Post-COVID syndrome
Disease: Version SOC Term Classification Code Term Level
24.0 100000004862 10085505 Post-COVID syndrome LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing)
Trial results: (No results available)

EudraCT Number: 2023-000135-76 Sponsor Protocol Number: ACE-01-22 Start Date: 2023-05-15
Sponsor Name: Adamed Pharma S.A.
Full Title: Therapeutic Equivalence Study of Twice Daily Acetylsalicylic Acid Tablets 50 mg Compared to Once Daily Acetylsalicylic Acid Tablets 100 mg in Adult Patients Coronary Artery Disease (CAD) or Symptom...
Medical condition: Coronary Artery Disease (CAD) or Symptomatic Peripheral Artery Disease (PAD) or after Acute Coronary Syndrome (ACS)
Disease: Version SOC Term Classification Code Term Level
20.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
21.1 100000004866 10067825 Peripheral arterial disease LLT
20.0 10007541 - Cardiac disorders 10051592 Acute coronary syndrome PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: PL (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-002818-13 Sponsor Protocol Number: DEALSZ-2021-001 Start Date: 2023-05-12
Sponsor Name: Charité-Universitätsmedizin Berlin
Full Title: A Randomized, Double-blind, Placebo-controlled, Phase 2, 12-Week Treatment Study with a 10-Week Follow-up Period to Assess the Efficacy and Safety of Benralizumab (anti-IL5Rα) in Adult Patients wit...
Medical condition: Chronic prurigo in adult patients. Chronic Prurigo is characterized by the presence of chronic pruritus, multiple localized or generalized, pruriginous lesions, and the history and/or signs of a p...
Disease: Version SOC Term Classification Code Term Level
20.0 10040785 - Skin and subcutaneous tissue disorders 10037083 Prurigo PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Completed)
Trial results: (No results available)

EudraCT Number: 2021-006456-14 Sponsor Protocol Number: K321301 Start Date: 2023-05-10
Sponsor Name: Kowa Research Institute, Inc.
Full Title: A Double-Masked, Randomized, Placebo-Controlled, Parallel-Group, 12-Week Administration With Two-Week Gradual Dose Taper Phase and 38-Week Follow-Up Phase, Phase 3 Study to Investigate the Safety ...
Medical condition: In Fuchs endothelial corneal dystrophy (FECD), there is an increased rate of loss of endothelial cells, starting in the centre of Descemet’s membrane and spreading to the periphery, resulting in ex...
Disease: Version SOC Term Classification Code Term Level
20.0 10010331 - Congenital, familial and genetic disorders 10011005 Corneal dystrophy PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing) DK (Ongoing) ES (Ongoing)
Trial results: (No results available)
EudraCT Number: 2021-005245-32 Sponsor Protocol Number: CF102-212LD Start Date: 2023-05-09
Sponsor Name: CanFite BioPharma Ltd.
Full Title: A Phase 2B Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Namodenoson in the Treatment of Non-Alcoholic Steatohepatitis (NASH)
Medical condition: Non-Alcoholic Steatohepatitis (NASH) and F1-3 fibrosis.
Disease: Version SOC Term Classification Code Term Level
24.1 10019805 - Hepatobiliary disorders 10053219 Non-alcoholic steatohepatitis PT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: BG (Ongoing)
Trial results: (No results available)

EudraCT Number: 2022-003526-50 Sponsor Protocol Number: HACOL-ACS Start Date: 2023-05-09
Sponsor Name: Hannover Medical School
Full Title: A prospective, interventional, single-center, single-arm study to assess the effectiveness of Bempedoic acid to achieve LDL-cholesterol targets in patients following ST-elevation or Non-ST-elevatio...
Medical condition: Patients following acute percutaneous coronary intervention for STEMI or NSTEMI insufficiently treated with high-intensity oral lipid lowering therapy
Disease: Version SOC Term Classification Code Term Level
20.0 10007541 - Cardiac disorders 10064345 ST segment elevation myocardial infarction LLT
20.0 10007541 - Cardiac disorders 10064347 Non ST segment elevation myocardial infarction LLT
Population Age: Adults, Elderly Gender: Male, Female
Trial protocol: DE (Ongoing)
Trial results: (No results available)